Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886695 | 0.90 | MAPK8 (0.36) | LMNAALDH1A1MAPTSMN1; SMN2POLB | |
| SCHEMBL5887292 | 0.88 | ALDH1A1 (0.40) | LMNAALDH1A1MAPTSMN1; SMN2POLB | |
| SCHEMBL5887202 | 0.87 | BRAF (0.38) | LMNAALDH1A1MAPTSMN1; SMN2NAMPT | |
| SCHEMBL5887261 | 0.86 | RORC (0.37) | LMNAALDH1A1MAPTNAMPT | |
| SCHEMBL5887095 | 0.85 | ALDH1A1 (0.44) | LMNAALDH1A1MAPTTHRBPDE4A | |
| SCHEMBL5887398 | 0.84 | ALDH1A1 (0.43) | LMNAALDH1A1MAPTTHRBSMN1; SMN2 | |
| SCHEMBL5886714 | 0.84 | ALDH1A1 (0.45) | LMNAALDH1A1MAPTTHRBSMN1; SMN2 | |
| SCHEMBL5887408 | 0.83 | PPARG (0.35) | NAMPTRXFP1TP53RECQL | |
| SCHEMBL5886866 | 0.83 | SMN1; SMN2 (0.50) | LMNAALDH1A1MAPTSMN1; SMN2NAMPT | |
| SCHEMBL5886975 | 0.83 | MAPT (0.47) | LMNAALDH1A1MAPTSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | LMNA 711/4885ALDH1A1 1860/4885MAPT 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.